EFTA00346026.pdf

From: "Jeffrey E." -4 To: Subject: Fwd: Date: Thu, 02 Jul 2015 18:26:25 +0000 Forwarded message From: Jeffrey Port < Date: Thu, Jul 2, 2015 at 7:37 PM Subject: RE: To: "jeffrey E." Jeff Can we do something early on the 9th JP From: jeffrey E. [mailto: Sent: Thursday, July 02, 2015 10:52 AM To: Jeffrey Port Subject: Re: i will be back either the 9th or the 14th, either day would be fine. look forward to meeting you On Thu, Jul 2, 2015 at 4:41 PM, Jeffrey Port < wrote: Jeff Hope all well Wanted to provide the numbers for Angiocrine In summary, we are heading out by summers end for a series B raise at a 50 million pre money valuation. We are offering a 25% discount to the series b , and looking to bolster our financials for the raise with an additional 5 million in capital. Overall, I think a very good deal. Paul Finnegan , our CEO, and I are available next week in NY if you wish to discuss live If you have interest let me know Best regards EFTA00346026 Jeff Port (c please note The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of JEE Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved please note The information contained in this communication is confidential, may be attorney-client privileged, may constitute inside information, and is intended only for the use of the addressee. It is the property of JEE Unauthorized use, disclosure or copying of this communication or any part thereof is strictly prohibited and may be unlawful. If you have received this communication in error, please notify us immediately by return e-mail or by e-mail to and destroy this communication and all copies thereof, including all attachments. copyright -all rights reserved EFTA00346027